Neuroimaging biomarkers in the biological definition of Parkinson’s disease and dementia with Lewy bodies – EANM position on current state, unmet needs and future perspectives.

The article focuses on advancing the biological definitions of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) through novel biomarker-driven frameworks like SyNeurGe and NSD-ISS, analogous to the ATN system in Alzheimer's disease. Topics include the integration of α-synucleinopathy detection using seed amplification assays in cerebrospinal fluid and skin, alongside neurodegeneration and dopaminergic deficit assessments via imaging biomarkers.